Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
Title | Type | $ Amount | Activity |
Investigator![]() |
Unit | Sponsor | Date |
---|---|---|---|---|---|---|---|
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable.. | Contract | $171,440.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Incyte Corporation | 05/2020 |
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-Type, Left-Sided Colorectal Cancer | Contract | $127,173.74 | Clinical Trial | Aaron Scott | Cancer Center Division | Academic Gastrointestinal Cancer Consortium | 03/2020 |
A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab +/- Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metas | Contract | $404,272.70 | Clinical Trial | Aaron Scott | Cancer Center Division | Leap Therapeutics, Inc. | 10/2020 |
A Phase 3, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Pembrolizumab + Lenvatinib + Chemotherapy Induction Therapy Followed by Pembrolizumab + Lenvatinib Compared with… | Contract | $500.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Merck Sharp & Dohme Corp. | 02/2021 |
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator Phase 2/3 study of Tucatinib in Combination with Trastuzumab, Ramucirumab, and Paclitaxel in Subjects with Previously Treated, Locally | Contract | $453,804.20 | Clinical Trial | Aaron Scott | Cancer Center Division | Seagen Inc. | 01/2021 |
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction... | Contract | $105,851.40 | Clinical Trial | Aaron Wolfson | Sarver Heart Center | Cytokinetics, Incorporated | 09/2020 |
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel.. | Contract | $327,830.00 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Covance, Incorporated | 01/2020 |
A Phase II Trial of PET-Directed Therapy using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin Plus Nivolumab, Foll | Contract | $40,100.00 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Mayo Foundation for Medical Education and Research (Mayo Clinic) | 06/2020 |
Accuracy of Arthroscopic vs. Open Reduction of Ankle Syndesmosis Injuries | Contract | $5,000.00 | Research Training | Aditya Manoharan | Orthopaedic Surgery | Orthopaedic Research and Education Foundation | 04/2020 |
A Randomized Controlled Trial to Improve Mother-Infant Synchrony Among Women with Childhood Adversity | Grant | $2,437,784.00 | Research | Aleeca Bell | College of Nursing | National Institute of Nursing Research | 09/2020 |
A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies | Contract | $468,451.00 | Clinical Trial | Alejandro Recio Boiles | Cancer Center Division | Atreca, Inc. | 10/2020 |
A Novel Approach to Help Women of Reproductive Age Quit Smoking | Grant | $100,000.00 | Research | Alicia Allen | Family and Community Medicine | Prevent Cancer Foundation | 04/2020 |
Hormonal Response to Infant Caregiving: A Novel Strategy to Break the Opioid Relapse Cycle During The Postpartum Period | Grant | $2,302,500.00 | Research | Alicia Allen | Family and Community Medicine | Eunice Kennedy Shriver National Institute of Child Health and Human Development | 09/2020 |
Arizona Anesthesia Solutions Professional Agreement | Contract | $499,200.00 | Other Sponsored Activity | Allen Prettyman | College of Nursing | Arizona Anesthesia Solutions | 08/2020 |
COVID-19's Impact on Insurance Coverage and Cancer Treatment | Grant | $40,000.00 | Research | Amanda Arrington | Surgery | Society for Surgery of the Alimentary Tract | 09/2020 |
Validation of Spinal Neurotensin Receptor 2 as an Analgesic Target | Grant | $1,539,731.00 | Research | Amol Patwardhan | Anesthesiology | National Institute of Neurological Disorders and Stroke | 10/2020 |
Regulation of P-Body Formation and mRNA Decapping in Cancer: Control by AKT and Pim Kinase Phosphorylation of EDC3 | Grant | $394,690.00 | Research | Andrew Kraft | Cancer Center Division | National Cancer Institute | 07/2020 |
Retrospective Independent Safety Review of Closed Irrisept Study | Contract | $42,700.00 | Clinical Trial | Andrew Tang | Surgery | IrriMax Corporation | 10/2020 |
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | Grant | $174,073.00 | Research | Anne Cress | Cellular & Molecular Medicine | Aqualung Therapeutics, Corp. | 10/2020 |
Integrative Cancer Scholars Training Grant | Grant | $1,382,000.00 | Research Training | Anne Cress | Cancer Center Division | National Cancer Institute | 10/2020 |
In Vivo Screening of Candidate Therapeutic Antibodies in Preclinical Models of Prostate Cancer | Contract | $31,231.00 | Research | Anne Cress | Cellular & Molecular Medicine | Aqualung Therapeutics, Corp. | 02/2020 |
The Role of Ryanodine Receptors in Drug Seeking | Grant | $1,430,743.00 | Research | Arthur Riegel | Pharmacology | National Institute on Drug Abuse | 02/2020 |
The MITRAL Trial (Mitral Implantation of TRAnscatheter VaLves is Native Mitral Stenosis) | Contract | $62,000.00 | Clinical Trial | Ashish Pershad | COM Phx Internal Medicine | Mayo Foundation for Medical Education and Research (Mayo Clinic) | 01/2020 |
A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Repair with the Edwards PASCAL Transcatheter ...... | Contract | $141,792.00 | Clinical Trial | Ashish Pershad | COM Phx Internal Medicine | Edwards Lifesciences LLC | 06/2020 |
Clinical Study of the BioVentrix Revivent TC System for Treatment of Left Ventricular Aneurysms | Contract | $194,732.72 | Clinical Trial | Ashish Pershad | COM Phx Internal Medicine | BioVentrix, Inc. | 08/2020 |